CHENGDU, China.--(BUSINESS WIRE)—Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific Advisory Board (SAB) comprised of internationally-renowned experts in the vaccine industry, public health and policy making. The SAB will provide strategic oversight and guidance to the global development of Clover’s protein-based COVID-19 S-Trimer vaccine programs.
Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, commented: “We are honored to welcome these leading vaccine experts to our newly-formed SAB. The SAB will provide a valued source of counsel as we continue to rapidly develop our COVID-19 S-Trimer vaccine. With a broad range of backgrounds, the SAB will serve a valuable role in advising Clover in all aspects of our global vaccine development and access in the critical months to come.”
Ralf Clemens, M.D., Ph.D., Chairman of the SAB, added: “I am pleased to lead this team of leaders in vaccine and immunization with diverse and complementary expertise and decades of experience to support Clover in the innovative work that they are doing with the COVID-19 S-Trimer vaccine utilizing their proprietary Trimer-Tag© technology. All of the SAB members share in Clover’s vision of developing and producing a safe, effective and accessible vaccine that can provide much needed relief to communities around the world to contain this pandemic.”
Clover’s SAB includes the following members:
Ralf Clemens, M.D., Ph.D., Chairman of the SAB, former Senior Vice President / Global Head of Vaccine Development at Takeda, Novartis Vaccines and GSK; former Member Board of Trustees, International Vaccine Institute (IVI).
Donna Ambrosino, M.D., Research Advisor, former Chief Executive Officer, Nosocomian Vaccine Corp; former Chief Executive Officer, MassBiologics and Professor of Pediatrics, University of Massachusetts Medical School.
Sue Ann Costa Clemens, M.D., Ph.D., Clinical Development Advisor, Visiting Professor of Global Health, Oxford University; Director Vaccine Group Oxford-Brazil; Professor and Head of Institute for Global Health, Universita di Siena; former Vice President of Vaccine Development (Latin America), GSK.
Pierre Desmons, Ph.D., CMC Advisor, former Vice President, Head of R&D China and Head of Asia Strategic Partnerships, GSK.
Sam Liao, Business Development & Strategy Advisor, former Head of Business Development and Licensing (Asia), Novartis Vaccines; former Director of Corporate Development, Sanofi.
Michael Pfleiderer, Ph.D., Regulatory Affairs Advisor, Principal Consultant, Biopharma Excellence; former Head of Viral Vaccines Section, Paul-Enrlich-Institut (PEI); former Chair of Pandemic Task Force (2009/10), European Medicines Agency (EMA).
Peter Richmond, MBBS MCRP(UK) FRACP, Medical Advisor, Head of Division of Paediatrics (Faculty of Health & Medical Sciences), The University of Western Australia; Head of Vaccine Trials Group, Telethon Kids Institute.
Antoinette Quinsaat, Project Management Advisor, former Head of Clinical Operations (International), GSK Biologicals and Novartis Vaccines; former Head of Study Management (Asia Pacific), Sanofi.
Frank Rockhold, Ph.D., Biostatistics Advisor, Professor of Biostatistics and Bioinformatics, Duke University Medical Center; Managing Partner, HunterRockhold Inc; former Senior Vice President and Chief Safety Officer, GSK.
David Salisbury, Public Health Advisor, former Director of Immunization, Department of Health (London); former Chair of Strategic Advisory Group on Immunization, World Health Organization (WHO); former Co-chair of Pandemic Influenza Group, G7 Global Health Initiative.
George Siber, M.D., Research Advisor, Co-founder, Affinivax; former Executive Vice President and Chief Scientific Officer, Wyeth Vaccines; former Associate Professor of Medicine, Infectious Diseases, Harvard Medical School.
Nelson Teich, M.D.,MSc, Public Health Advisor, former Minister of Health, Brazil; Founder and former President, Integrated Clinical Oncology Group (COI) and COI Management, Education and Research Institute.
Anh Wartel, M.D., Clinical Development Advisor, Associate Director General, International Vaccine Institute (IVI); former Senior Director of Clinical R&D, Regional Medical Expert, and Country Medical Head (Vietnam/Cambodia), Sanofi.
Nicholas Jackson, Ph.D., SAB Observer, Head of Programs and Innovation, CEPI; former Vice President and Head of Global Research, Sanofi.